Navigation Links
Henry Ford West Bloomfield Hospital Launches Gene Therapy Study for Parkinson's Disease
Date:10/6/2009

WEST BLOOMFIELD, Mich., Oct. 6 /PRNewswire/ -- Henry Ford West Bloomfield Hospital is embarking on a research study for advanced Parkinson's disease using a state-of-the-art treatment called gene transfer.

The clinical trial will test whether gene transfer therapy is able to restore better mobility in Parkinson's patients who have lost responsiveness to drug therapy.

"The start of this clinical trial provides hope to a Parkinson's disease patient population that has had a long-standing need for better treatment options," says Henry Ford West Bloomfield Hospital neurologist Peter LeWitt, M.D.

Parkinson's disease is a degenerative disorder of the central nervous system that causes tremors and impairs a person's motor skills, speech, balance and posture. Its cause is unknown and it affects 1 percent to 2 percent of people over the age of 60.

Of the eight sites in the United States involved in the study, Henry Ford West Bloomfield Hospital is the only Michigan institution testing this experimental therapy.

A small region deep within the brain is the source for the symptoms of Parkinson's disease. When brain neurons in this part of the brain begin to die, these cells can no longer manufacture the molecule dopamine, a chemical critical for controlling movement.

Among patients with Parkinson's disease, the pace and extent of progression in neurologic deficits can greatly vary. The burden on quality of life spans a wide spectrum too, Dr. LeWitt says, from minimal discomfort and disability to marked impairment of capabilities such as independence, safety and communication.

Most current therapies and research approaches target dopamine to treat motor symptoms associated with Parkinson's disease. In contrast, the focus of the current gene therapy strategy is on increasing GABA, a brain neurotransmitter that regulates movement. In Parkinson's disease, GABA is reduced in an area of the brain called the subthalamic nucleus, causing it to be overactive. Investigators feel this might be a better way to help advanced Parkinson's disease.

For the clinical trial, the gene therapy product rAAV-GAD will be placed into the subthalamic nucleus by a surgical procedure. The gene transfer is done through a catheter that is removed shortly after its placement. Participants will be assessed post-treatment at multiple intervals. As an alternative to this experimental treatment, patients with advanced Parkinson's disease have the option of deep brain stimulation. This also involves a surgical procedure in which a pacemaker-like device is placed in the brain to help in control of Parkinson's disease symptoms.

LeWitt notes that the Henry Ford Parkinson's Disease and Movement Disorders Program is devoted to bringing the most promising therapies. This program is also working with experimental approaches for slowing progression of Parkinson's disease.

To learn more about the study, call 248-355-2452.

About Henry Ford Parkinson's Disease and Movement Disorders Program

The Henry Ford Parkinson's Disease and Movement Disorders Program is a Center of Excellence based in Southfield and at other Henry Ford locations. It provides treatment and research for Parkinson's disease, tremors, and other movement disorders. The Henry Ford program provides routine diagnostic services and treatment for Parkinson's disease, as well as several investigational studies for new treatments. Research carried out is searching for better treatments and possible ways to arrest the progression of Parkinson's disease, including neuroprotection strategies and an upcoming gene therapy clinical trial.

SOURCE Henry Ford Health System


'/>"/>
SOURCE Henry Ford Health System
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Henry Ford Macomb Hospital Deploys PerfectServe at Warren Campus to Improve Communication, Better Coordinate Care
2. Henry Ford Hospital Offers Free Prostate Cancer Screenings
3. Apollo PACS, Inc. Selected by Henry Ford Health System for Its Digital Pathology Solution
4. Henry Schein to Present at the Morgan Stanley Global Healthcare Unplugged Conference
5. 12th Annual Henry Schein Back-to-School Events Help 2,000 Underserved Children Return to the Classroom in Style
6. Henry M. Jackson Foundation names fellowship award winners
7. Atlanta Sleep Medicine Clinic Views Representative Henry Waxman's Denial of Restless Leg Syndrome as a Sign of General Lack of Awareness of the Sleep Disorder
8. CSC Signs $115 Million IT Services Renewal Agreement With Henry Ford Health System
9. Oklahoma Passes Comprehensive Tort Reform: Governor Brad Henry Signs Reform Legislation
10. Henry Ford Hospital: Unique Patient Study -- No Informed Consent
11. Doctors at Henry Ford Health System Treat Ovarian, Prostate, Lung, and Other Forms of Cancer Using Novalis Tx(TM) Platform for Image-Guided Radiosurgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Diego, CA (PRWEB) , ... December 05, 2016 , ... ... seen and heard the dangers and downsides of patients who do not do their ... The field of cosmetic dermatology is in the midst of a renaissance and every ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... Rejuvenation" at the 2016 Anti-Aging & Beauty Awards at The Aesthetic & ... & Anti-aging Medicine European Congress (AMEC) brings together the industry’s leading scientific ...
(Date:12/5/2016)... ... December 05, 2016 , ... A ... Patch® significantly improves the reproducibility and accuracy of placing precordial electrodes with little ... , Over the last 60 years, studies have shown that single electrode misplacement ...
(Date:12/4/2016)... ... 03, 2016 , ... The Lymphoma Research Foundation (LRF) – ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... New York City, with long-time partners The Paul Foundation, on November 10, 2016. ...
(Date:12/4/2016)... , ... December 03, 2016 , ... While James Earl ... serving as host for in a show called "Front Page". One of the forthcoming ... years, breast cancer rates have plummeted in large part due to early detection. Like ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... India , December 5, 2016 According ... by Treatment modalities (Chondrocyte Transplantation, Growth Factor Technology, Tissue Scaffolds, Cell-free ... published by MarketsandMarkets, the market is projected to reach USD 779.8 ... a CAGR of 13.5% during the forecast period of 2016 to ... ...
(Date:12/5/2016)... Sanovas, Inc., a life science asset holding company ... wholly owned subsidiary, Intubation Science, Inc., and its LightSpeed Intubation ... http://photos.prnewswire.com/prnh/20161202/445251LOGO   ... Sanovas, Inc. ... There are over 40 million Endotracheal Intubations performed annually ...
(Date:12/5/2016)... WOONSOCKET, R.I. , Dec. 5, 2016 /PRNewswire/ ... CVS ) Research Institute and the U.S. ... the Assistant Secretary for Preparedness and Response (ASPR), ... showed that automated pharmacy notifications encourage patients ... a forecasted natural disaster. The study also affirms ...
Breaking Medicine Technology: